Sartorius Stedim Biotech and Sensible Biotechnologies Collaborate to Scale Up Cell-Based mRNA Production Platform
Thursday, July 10, 2025
Sartorius Stedim Biotech, a global partner to the biopharmaceutical industry, has entered into a Memorandum of Understanding (MoU) with Sensible Biotechnologies to advance the scale-up of Sensible’s cell-based platform for mRNA design and manufacturing. The partnership aims to support the clinical-grade production of cell-based mRNA by 2026, paving the way for next-generation mRNA-based therapeutics.
Sartorius has already contributed advanced equipment and consumables to the collaboration. Going forward, the partnership will focus on process development, closed-system facility design, and technical support to help establish GMP-compliant manufacturing capabilities. This effort will support Sensible’s expansion beyond Slovakia to regions including the United States, United Kingdom, and wider Europe.
The initiative is intended to deliver mRNA with enhanced purity and performance, suitable for therapeutic applications. The agreement also outlines the potential for future collaboration, reinforcing both companies’ shared commitment to building scalable and high-quality mRNA production infrastructure worldwide.
Source: sartorius.com
